Background: Trans-urethral resection of tumor (TURT) is the main treatment of non-muscle invasive urothelial carcinoma, but it is associated with high rate of recurrence and or progression, this arouses the need for adjuvant therapy. Topoisomerase II, KI67 and P53 are proliferation and cell cycle regulator markers that may predict tumor response to therapy.
Aim: This study aimed to assess Top II, KI67 and P53 expression on clinical outcome and response to therapy of non-muscle invasive urothelial carcinoma.
Material and methods: Fifty cases of non-muscle invasive urothelial carcinoma were collected; Top II, KI67, and P53 expression were evaluated. Patients received treatment then recurrence was correlated with the expression of previous markers.
Results: There was a significant association between high Top II score, P53 and Ki67 and high grade (P= 0.0001, 0.001, 0.0001), submucosal infiltration (P= 0.0001, 0.01) and recurrence (P=0.01, 0.001, 0.001).
Conclusion: Top II, P53, and Ki-67 may predict response to therapy and the clinical outcome in non-muscle invasive urothelial carcinoma.